WASHINGTON (dpa-AFX) - Myriad Genetics Inc. (MYGN) announced that it has signed an agreement with Pharma Mar, a developer of marine-derived drugs.
As per the agreement, Myriad will conduct BRCA 1 and BRCA 2 testing on patients to be enrolled in a Phase II clinical study of PM1183, a novel drug candidate which induces double-stranded DNA breaks to cause cell death.
As per the agreement, Myriad will assess the BRCA status in patients who respond to PM1183. Myriad noted that it has entered into similar agreements with Abbott Pharmaceuticals, Astra Zeneca, BioMarin Pharmaceuticals and Cephalon to provide companion diagnostic testing with the BRACAnalysis test for clinical trial enrollment.
Copyright RTT News/dpa-AFX
